Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Linical Co., Ltd. ( (JP:2183) ) is now available.
Linical Co., Ltd. reported a decline in its consolidated financial results for the six months ended September 30, 2025, with net sales dropping by 10.4% compared to the previous year. The company experienced a significant decrease in operating income and profit attributable to owners of the parent, indicating financial challenges. Despite these results, the company has maintained its dividend forecast for the fiscal year ending March 31, 2026, suggesting a commitment to shareholder returns.
The most recent analyst rating on (JP:2183) stock is a Hold with a Yen348.00 price target. To see the full list of analyst forecasts on Linical Co., Ltd. stock, see the JP:2183 Stock Forecast page.
More about Linical Co., Ltd.
Linical Co., Ltd. is a company listed on the Tokyo Stock Exchange, primarily engaged in the clinical research industry. It provides services related to clinical trials and drug development, focusing on the pharmaceutical and biotechnology sectors.
Average Trading Volume: 19,378
Technical Sentiment Signal: Sell
Current Market Cap: Yen7.91B
For an in-depth examination of 2183 stock, go to TipRanks’ Overview page.